Elkem ASA - Notice of extraordinary general meeting

Elkem has entered a Share Purchase Agreement to sell the majority of its Silicones division to Bluestar, to be settled using all Elkem shares currently held by Bluestar, and will hold an extraordinary general meeting on 9 March 2026 to vote on approval of the SPA and the redemption of Bluestar’s shares. The transaction and proposed share redemption represent a significant corporate restructuring and potential governance change for Elkem; the company reported NOK 31 billion in operating income in 2025. Shareholders will vote digitally via Lumi AGM; full documentation is available on Elkem’s investor website.

Analysis

Market structure: The contemplated sale of Elkem’s majority Silicones division to Bluestar (settled via Bluestar’s Elkem shares) is a de facto asset-for-equity consolidation that should concentrate silicones production under Bluestar while reducing Elkem’s share count via the proposed redemption at the 9 March 2026 EGM. Winners: remaining Elkem public shareholders (share-count reduction → EPS/NAV uplift) and Bluestar (larger silicones scale); Losers: standalone silicones peers facing a larger integrated competitor and Elkem’s near-term revenue base which will shrink. Expect a near-term positive price reaction to the accretion story but a mid/long-term re-rating dependent on how much EBITDA is divested versus retained cash/proceeds.

Risk assessment: Tail risks include regulatory blocking (Norwegian/Chinese antitrust or foreign investment review), minority-shareholder litigation over related-party terms, and an adverse earnings mix if silicones were a high-margin component—each could reverse gains. Timeline: immediate volatility (days) around the announcement and EGM (9 Mar 2026), short-term (weeks–3 months) for shareholder approval and public scrutiny, and medium-term (3–12 months) for regulatory clearances and reporting of post-transaction adjusted leverage. Watch leverage/EBITDA thresholds—if net leverage moves above ~2.5x post-transaction, credit spreads should widen materially.

Trade implications: Direct play — establish a tactical 2–3% long in Elkem (ELK.OL) into the EGM, targeting +12–20% on approval, with a 12% hard stop; size optionality with a buy-call-spread (buy Jun 2026 ATM call, sell Jun 2026 15% OTM call) equal to ~50% of the equity position to cap premium. Pair trade — long ELK vs short Wacker Chemie (WCH.DE) 0.8x notional to capture relative outperformance from share-redemption and focus benefits; take profit when ELK outperforms WCH by 10%. Fixed income — trim exposure to Elkem senior bonds if credit metrics deteriorate or buy protection if spreads tighten <50bp expecting equity-led recovery.

Contrarian angles: Consensus expects clean accretion; what’s missed is that Elkem may give up a stable, possibly high-margin cash generator—this could reduce dividend capacity and increase earnings cyclicality, a value trap if proceeds are mostly share transfers with limited cash. Historical parallels show related-party asset swaps can be renegotiated or litigated; therefore positions should be sized with regulatory and legal risk in mind and rebalanced at clear binary outcomes (EGM approval, regulatory clearance within 3–9 months). Monitor disclosed deal valuation metrics and any conditionality in the SPA closely—those specifics will determine whether the market reaction is overdone or justified.

Key Decisions for Investors

• Establish a 2–3% long position in Elkem (ELK.OL) before the EGM on 9 Mar 2026; target a 12–20% upside on approval and set a hard stop at -12% to limit event risk.
• Buy a Jun 2026 call spread on ELK (buy ATM call, sell 15% OTM call) sized to ~50% of the equity position to capture upside while limiting premium; unwind 2 trading days after EGM if approved or immediately on any adverse regulatory news.
• Implement a paired relative-value trade: long ELK (notional X) and short Wacker Chemie (WCH.DE) ~0.8x notional to exploit potential relative re-rating; close when ELK outperforms WCH by +10% or at 6 months.
• Reduce direct exposure to Elkem corporate bonds/bond allocations by 25% if management discloses post-sale net leverage >2.5x EBITDA or if bond spreads widen >75bp; consider buying CDS protection if leverage guidance deteriorates.